Skip to main content
. 2024 Mar 15;17:138. doi: 10.1186/s13071-023-06089-1

Table 2.

Prior distributions derived from previous literature for the disease prevalence and performance characteristics of the tests

Models Prior distribution
Prevalence Leukoconcentration TBS-50/direct blood examination
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
I Beta(4.61,48.21) Beta(52.21,0.33) Beta(202.31,30.25) Beta(84.49,29.75) Beta(122.37,0.33) Beta(15.72,8.02) Beta(63.65,0.33) Beta(10.73,0.33) Beta(80.46,6.36)
II Beta(1,1) Beta(1,1)T(1-sp[1])a Beta(1,1) Beta(1,1) Beta(1,1) Beta(1,1)T(1-sp[1]) Beta(1,1) Beta(1,1) Beta(1,1)
III Beta(4.61,48.21) Beta(1,1)T(1-sp[1]) Beta(1,1) Beta(1,1) Beta(1,1) Beta(1,1)T(1-sp[1]) Beta(1,1) Beta(1,1) Beta(1,1)

PPV positive predictive value, NPV negative predictive value

aT(1-sp[1]) = technical term used in JAGS (Just Another Gibbs Sampler) software when defining the formula of the Hui-Walter BLCA model. This addition to the default formula is a safeguard that would have an effect in scenarios when JAGS estimates the Se/Sp to be 0%. This additional “T(1-sp[1])” component of the prior then forces JAGS to consider this Se/Sp as 100% instead, as 0% Se/Sp = 100% Se/Sp after simply switching the labeling of the test results. For the models used in this paper, inclusion/exclusion of “T(1-sp[1])” had no effect on the estimates of the test performance characteristics, meaning that this safeguard remained unused

To calculate priors for the thick smear test, data from Noireau and Apembe [28] were used. Se: 66.7% (49.8–80.9); Sp: 100.0% (97.7–100.0); PPV: 100.0% (86.8–100.0); NPV: 93.0% (87.6–96.0). For the leukoconcentration, data from Bouyou-Akotet et al. [36] were used: Se: 100% (97.2–100.0); Sp: 87.1% (83.2–90.5); PPV: 74.1% (67.0–80.5); NPV: 100.0% (98.8–100.0)